---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000034"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:27:14.828093+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AbbVie expects Q2 2025 acquired IPR&D expense of $823M, lowers adjusted EPS guide

## Summary
- Acquired IPR&D and milestones expense of $823M pre-tax in Q2 2025 reduces GAAP and adjusted EPS by $0.42.
- Full-year 2025 adjusted diluted EPS guidance range lowered to $11.67-$11.87 from $12.09-$12.29.
- Q2 2025 adjusted diluted EPS guidance range now $2.84-$2.88 versus prior $3.26-$3.30.
- Guidance excludes any acquired IPR&D expense beyond Q2 2025 due to forecasting uncertainty.
- Q2 2025 results are preliminary and subject to financial statement closing procedures.

## SEC filing metadata
- accession: 0001551152-25-000034
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000034/0001551152-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000034/abbv-20250703.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000034
- JSON: https://secwatch.observer/filing/0001551152-25-000034.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.